Skip to main navigation
Skip to search
Skip to main content
Ariel University Home
Help & FAQ
Link opens in a new tab
English
עברית
العربية
Search content at Ariel University
Home
Profiles
Research units
Equipment
Research output
Prizes
Activities
Press/Media
Surveillance of infectious complications in hemato-oncological patients
Ron Ram
, Anat Gafter-Gvili
, Pia Raanani
, Moshe Yeshurun
, Ofer Shpilberg
, Juliet Dreyer
, Anat Peck
, Leonard Leibovici
, Mica Paul
Research output
:
Contribution to journal
›
Article
›
peer-review
11
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Surveillance of infectious complications in hemato-oncological patients'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Israel
100%
Infection Rate
100%
Oncology Patients
100%
Infectious Complications
100%
Neutropenia
100%
Haematology Unit
100%
Fungal Infection
66%
Acute Leukemia
66%
Invasive Fungal Infection
66%
Incidence Rate
33%
High Risk
33%
Bacterial Infection
33%
Low Risk
33%
Surveillance Studies
33%
Epidemiology
33%
Hospital Days
33%
Infection Risk
33%
Prospective Surveillance
33%
Patient Admission
33%
Hematology
33%
Induction Therapy
33%
Patients with Hematological Malignancies
33%
Background Monitoring
33%
Infection Surveillance
33%
Uniform Guidelines
33%
Nursing and Health Professions
Infection
100%
Ward
100%
Infectious Complication
100%
Neutropenia
100%
Infection Rate
66%
Mycosis
66%
Acute Leukemia
66%
Systemic Mycosis
66%
Practice Guideline
33%
Outpatient Department
33%
Bacterial Infection
33%
Hematologic Malignancy
33%
Epidemiology
33%
Pharmacology, Toxicology and Pharmaceutical Science
Infection
100%
Infectious Complication
100%
Neutropenia
100%
Infection Rate
66%
Mycosis
66%
Acute Leukemia
66%
Systemic Mycosis
66%
Hematologic Malignancy
33%
Bacterial Infection
33%
Epidemiology
33%
Medicine and Dentistry
Hematology
100%
Infectious Complication
100%
Infection
75%
Neutropenia
75%
Infection Rate
50%
Mycosis
50%
Systemic Mycosis
50%
Acute Leukemia
50%
Hematologic Malignancy
25%
Cohort Effect
25%
Bacterial Infection
25%